Yunnan Baiyao Group Co.,Ltd

000538

CNE0000008X7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 23/05/2024 BST			5-day change	1st Jan Change
53.92 ^CNY	-0.20%		-2.51%	+9.70%

05-13	Yunnan Baiyao's Unit to Conduct Clinical Trials on Prostate Cancer Drug	MT
05-13	Yunnan Baiyao to Conduct Clinical Trials on Flurbiprofen Gel Patch	MT

Shanghai Pharmaceuticals Holding Co., Ltd announced that it has received CNY 13.974552334 billion in funding from Yunnan Baiyao Group Co.,Ltd, Shanghai Tandong Enterprise Consulting Services Co., Ltd.

March 24, 2022

On March 25, 2022, Shanghai Pharmaceuticals Holding Co., Ltd closed the transaction. The company received CNY 13,974,553,186.44 in the transaction. The investor Shanghai Tandong Enterprise Consulting Services Co., Ltd. issued 187,000,000 shares for proceeds of CNY 3,064,930,000 and Yunnan Baiyao Group Co.,Ltd issued 665,626,796 shares for proceeds of CNY 10,909,623,186.44.

Latest news about Yunnan Baiyao Group Co.,Ltd

Yunnan Baiyao's Unit to Conduct Clinical Trials on Prostate Cancer Drug	05-13	MT
Yunnan Baiyao to Conduct Clinical Trials on Flurbiprofen Gel Patch	05-13	MT
Yunnan Baiyao Group Co.,Ltd Announces Final Dividend on A Shares for the Year 2023, Payable on 10 May 2024	04-29	CI
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Yunnan Baiyao Group Co.,Ltd. Approves Cash Dividend for the Year 2023	04-23	CI
Yunnan Baiyao Group Co.,Ltd Proposes Final Cash Dividend for 2023	04-01	CI
Yunnan Baiyao Group's Profit Rises 30% as Operating Income Increases	04-01	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Shanghai Pharma, Yunnan Baiyao Renew Sales, Procurement Deal	12-22	MT
Yunnan Baiyao’s Profit Jumps 61% in Q3 as Revenue Rises 5%	31/10/23	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23	CI
YNBY International Plans Year-End Date Change	16/10/23	MT
Yunnan Baiyao’s Profit Jumps 88.5% in H1 as Revenue Rises 13%	30/08/23	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23	CI
Yunnan Baiyao Group Co.,Ltd. Approves Cash Dividend for the Year 2022, Payable on 19 May 2023	10/05/23	CI
Chinese Shares Rebound; Yunnan Baiyao Jumps 7.5% on Robust Q1 Earnings	27/04/23	MT
Yunnan Baiyao’s Q1 Profit Jumps 66% as Revenue Rises 11.5%; Shares Climb 7%	27/04/23	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	26/04/23	CI
Yunnan Baiyao Group Co.,Ltd's Equity Buyback announced on May 9, 2022, has expired.	06/04/23	CI
Yunnan Baiyao Group Co.,Ltd Proposes Final Cash Dividend for 2022	31/03/23	CI
Yunnan Baiyao Chairman Steps Down; Shares Fall 4%	07/03/23	MT
Yunnan Baiyao Group Co.,Ltd agreed to acquire Product Registration and Promotion, Global Supply and Professional Supporting Services of Ban Loong from Ban Loong Holdings Limited (SEHK:30).	22/12/22	CI
Yunnan Baiyao Group Co.,Ltd Announces Directorate Appointments	08/11/22	CI
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22	CI

Chart Yunnan Baiyao Group Co.,Ltd

Duration

Period

More charts

Company Profile

Yunnan Baiyao Group Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical products. The group proposes primarily traditional medicine products, phytobiological products, body care products, antibiotics and anti-inflammatory. China accounts for 98.9% of net sales.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Yunnan Baiyao Group Co.,Ltd

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

53.92 CNY

Average target price

64.08 CNY

Spread / Average Target

+18.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
YUNNAN BAIYAO GROUP CO.,LTD	+9.70%	13.28B
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals

Yunnan Baiyao Group Co.,Ltd

Equities

000538

CNE0000008X7

Pharmaceuticals

Shanghai Pharmaceuticals Holding Co., Ltd announced that it has received CNY 13.974552334 billion in funding from Yunnan Baiyao Group Co.,Ltd, Shanghai Tandong Enterprise Consulting Services Co., Ltd.

EPS Revisions